INTRODUCTION {#s1}
============

It is reported that about 14.1 million cancer patients and 8.2 million cancer-related deaths have occurred in 2012 worldwide \[[@R1]\]. In developing countries, the survival of cancer is poorer compared with the developed countries. The possible reason of this phenomenon is most likely due to limited access and lack of standard treatment. Cancer burden could be decreased through the application of tobacco control, healthier dietary intake, vaccine injection, early detection and treatment, and so on \[[@R2]\]. It is thought that cancer results from the interaction of individual\'s genetic components with environmental factors \[[@R3]\].

Peroxisome proliferator-activated receptor gamma (PPARG) involves three isoforms (e.g. PPARG1, PPARG2, and PPARG3). PPARG is an important nuclear receptor which acts as a transcriptional regulator and regulates energy metabolism \[[@R4]\]. In the pathological process of obesity, insulin insufficient/resistance and diabetes, PPARG may be activated, and then promotes the accumulation of fatty tissue \[[@R5]\]. PPARG agonists enhance insulin sensitivity \[[@R6]\]. PPARG may also possess anti-inflammatory roles \[[@R7], [@R8]\]. Activation of PPARG could inhibit the production of many cytokines \[e.g. tumor necrosis factor-alpha, interleukin (IL)-6, and IL-8\] by antagonizing the activities of the signal transducer and activator of transcription, transcription factors activator protein 1, and nuclear factor-kappa-B, which inhibits the induction of inflammatory response \[[@R9]\]. A number of case-control studies demonstrated that obesity, insulin resistance/insufficient, metabolic syndrome and inflammation were correlative conditions in which PPARG could modify and regulate these actions, and influence the risk of cancer \[[@R10]--[@R12]\].

Recently, a number of studies focused on the association of *PPARG* polymorphisms with cancer risk \[[@R13]--[@R28]\]. *PPARG* NM_015869.4:c.34C\>G (rs1801282 C\>G) and NM_138712.3: c.1347C\>T (rs3856806 C\>T) polymorphisms are two common single nucleotide polymorphisms (SNPs). A meta-analysis indicated the *PPARG* c.34C\>G polymorphism was associated with the risk of cancer in Asians \[[@R29]\]. However, the association of *PPARG* c.1347C\>T polymorphism with cancer risk was not found. Several meta-analyses did not identify the association between this SNP and cancer risk \[[@R30], [@R31]\]. Although more and more case-control studies focused on the relationship of the *PPARG* c.1347C\>T polymorphism with cancer susceptibility, the obtained findings remained conflicting. In addition, the association between this polymorphism and lung cancer was not studied in Asians. Therefore, in this study, we designed a case-control study and assessed the relationship between *PPARG* c.1347C\>T polymorphism and risk of non-small cell lung cancer (NSCLC) in Eastern Chinese Han population. Meta-analysis is a useful method of promoting the effective sample size by pooling of individual data from the enrolled studies, thus strengthening the power of the study for the assessment of genetic effects \[[@R32]\]. To address the association between *PPARG* c.1347C\>T polymorphism and cancer risk more precisely, we carried out a comprehensive meta-analysis.

RESULTS {#s2}
=======

Association of *PPARG* c.1347C\>T polymorphism with NSCLC {#s2_1}
---------------------------------------------------------

The risk factors, anthropometric data as well as demographics are listed in Table [1](#T1){ref-type="table"}. Body mass index (BMI) of controls was significantly higher than it in NSCLC group (*P* \< 0.001). This study was well-matched by age and gender. The SNP information of *PPARG* c.1347C\>T is shown in Table [2](#T2){ref-type="table"}. The genotyping success rate was 99.94% in 1,551 samples. Table [2](#T2){ref-type="table"} summarizes the minor allele frequency (MAF) of *PPARG* c.1347C\>T polymorphism and Hardy-Weinberg Equilibrium (HWE) in controls.

###### Distribution of selected demographic variables and risk factors in NSCLC cases and controls

  Variable         Overall Cases (*n* = 521)   Overall Controls (*n* = 1,030)   *P*^a^
  ---------------- --------------------------- -------------------------------- --------------
  Age (years)      59.76 ±10.71                60.34 ±9.11                      0.268
  Age (years)                                                                   0.843
   \< 60           238 (45.68)                 476 (46.21)                      
   ≥ 60            283 (54.32)                 554 (53.79)                      
  Sex                                                                           0.453
   Male            287 (55.09)                 588 (57.09)                      
   Female          234 (44.91)                 442 (42.91)                      
  Smoking status                                                                **\< 0.001**
   Never           317 (60.84)                 828 (80.39)                      
   Ever            204 (39.16)                 202 (19.61)                      
  Alcohol use                                                                   **\< 0.001**
   Never           444 (85.22)                 949 (92.14)                      
   Ever            77 (14.78)                  81 (7.86)                        
  BMI (kg/m^2^)    23.00 (±3.03)               23.84 (±3.06)                    **\< 0.001**
  BMI (kg/m^2^)                                                                 
   \< 24           337 (64.68)                 547 (53.11)                      **\< 0.001**
   ≥ 24            184 (35.32)                 483 (46.89)                      

^a^Two-sided *χ*^2^ test and Student t test

BMI: body mass index

###### Primary information for PPARG c.1347C\>T polymorphism

  Genotyped SNPs                             PPARG c.1347C\>T
  ------------------------------------------ -------------------
  Chromosome                                 3
  Function                                   coding-synonymous
  Chr Pos (NCBI Build 37)                    12475557
  MAF^a^for Chinese in database              0.25
  MAF in our controls (*n* = 1,030)          0.21
  *P* value for HWE^b^test in our controls   0.431
  Genotyping method                          SNPscan
  \% Genotyping value                        99.94%

^a^MAF: minor allele frequency.

^b^HWE: Hardy--Weinberg equilibrium.

The frequencies of *PPARG* c.1347 CC, CT and TT genotypes were 57.01%, 38.00% and 4.99% in 521 NSCLC patients and 61.32%, 34.50%, and 4.18% in 1,030 non-cancer controls, respectively. The genotype distribution of *PPARG* c.1347C\>T polymorphism is listed in Table [3](#T3){ref-type="table"}. In controls, the genotype distribution of this polymorphism was in accord with HWE. When compared with the frequency of c.1347 CC genotype, the frequency of c.1347 CT genotype was not difference between the NSCLC patients and controls (crude OR = 1.19, 95% CI: 0.95--1.48, *P* = 0.130). When compared with the frequency of c.1347 CC genotype, there was also no difference in the frequency of c.1347 TT genotype between the NSCLC patients and the controls (crude OR = 1.29, 95% CI: 0.78--2.13, *P* = 0.329). When c.1347 CC genotype was used as reference, there was also no difference in the frequency of c.1347 TT/CT genotype between the NSCLC patients and the controls (crude OR = 1.20, 95% CI: 0.97--1.48, *P* = 0.102). In addition, When c.1347 CC/CT genotype was used as reference, we found that there was no difference in the frequency of c.1347 TT genotype between the NSCLC patients and the controls (crude OR = 1.20, 95% CI: 0.73--1.98, *P* = 0.465). Adjustments for age, sex, BMI, smoking and drinking, as demonstrated in Table [3](#T3){ref-type="table"}, a tendency to increased NSCLC risk was noted (CT vs. CC: adjusted OR, 1.21; 95% CI, 0.96--1.53; *P* = 0.106; TT vs. CC: adjusted OR, 1.20; 95% CI, 0.71--2.04; *P* = 0.492, CT/TT vs. CC: adjusted OR, 1.21; 95% CI, 0.97--1.51; *P* = 0.097 and TT vs. CT/CC: adjusted OR, 1.12; 95% CI, 0.67--1.88; *P* = 0.671).

###### Logistic regression analyses of associations between PPARG c.1347C\>T polymorphism and risk of non-small cell lung cancer

  Genotype           Cases (n = 521)   Controls (n = 1,030)   Crude OR (95%CI)   P       Adjusted OR^a^ (95%CI)   P                           
  ------------------ ----------------- ---------------------- ------------------ ------- ------------------------ ------- ------------------- -------
  PPARG c.1347C\>T                                                                                                                            
  CC                 297               57.01                  631                61.32   1.00                             1.00                
  CT                 198               38.00                  355                34.50   1.19 (0.95--1.48)        0.130   1.21 (0.96--1.53)   0.106
  TT                 26                4.99                   43                 4.18    1.29 (0.78--2.13)        0.329   1.20 (0.71--2.04)   0.492
  CT+TT              224               42.99                  398                38.68   1.20 (0.97--1.48)        0.102   1.21 (0.97--1.51)   0.097
  CC+CT              495               95.01                  986                95.82   1.00                             1.00                
  TT                 26                4.99                   43                 4.18    1.20 (0.73--1.98)        0.465   1.12 (0.67--1.88)   0.671
  T allele           250               23.99                  441                21.43                                                        

^a^Adjusted for age, sex, smoking status, alcohol use and BMI status.

Meta-analysis of *PPARG* c.1347C\>T polymorphism and cancer risk {#s2_2}
----------------------------------------------------------------

Next, we carried out a pooled analysis to determine the potential relationship between *PPARG* c.1347C\>T polymorphism and overall cancer risk. A total of 35 abstracts were retrieved from searching of EMBASE and Pubmed databases. The selecting process of literature is presented in Figure [1](#F1){ref-type="fig"}. In total, there were 14 publications \[[@R17], [@R21], [@R23], [@R24], [@R33]--[@R42]\] and our case-control study recruited in this meta-analysis. Some publications involved several subgroups \[[@R17], [@R21], [@R24], [@R33], [@R34], [@R38], [@R40], [@R42]\], we treated them separately. If 1 cancer type was studied by \< 2 individual studies, then it was combined into the subgroup of 'other cancers'. The characteristic of the included studies and *PPARG* c.1347C\>T genotypes in different study are listed in Tables [4](#T4){ref-type="table"}, [5](#T5){ref-type="table"}. In total, 6,814 cases and 14,590 controls were enrolled in this meta-analysis.

![Flow diagram of the meta--analysis of the association between *PPARG* c.1347C\>T polymorphism and cancer risk](oncotarget-08-102277-g001){#F1}

###### Characteristics of the studies in meta-analysis

  Study                       Publication year   Ethnicity    Country           Cancer type               The origin of cancer cell   Sample size (case/control)   Genotype method   Scores
  --------------------------- ------------------ ------------ ----------------- ------------------------- --------------------------- ---------------------------- ----------------- --------
  Zhou et al. \[[@R40]\]      2000               Caucasians   USA               Glioblastoma              Non-epithelial tumor        52/80                        DGGE              4
  Zhou et al. \[[@R40]\]      2000               Caucasians   German            Glioblastoma              Non-epithelial tumor        44/60                        DGGE              4
  Smith et al. \[[@R34]\]     2001               Asians       Japan             bladder cancer            Epithelial tumor            31/27                        DGGE              2
  Smith et al. \[[@R34]\]     2001               Asians       Japan             cervical cancer           Epithelial tumor            20/27                        DGGE              2
  Smith et al. \[[@R34]\]     2001               mixed        USA               endometrial cancer        Epithelial tumor            69/80                        DGGE              2
  Smith et al. \[[@R34]\]     2001               Caucasians   UK                ovarian cancer            Epithelial tumor            31/65                        DGGE              2
  Smith et al. \[[@R34]\]     2001               Asians       Japan             ovarian cancer            Epithelial tumor            28/27                        DGGE              2
  Smith et al. \[[@R34]\]     2001               mixed        USA               ovarian cancer            Epithelial tumor            26/80                        DGGE              2
  Smith et al. \[[@R34]\]     2001               mixed        USA               prostate cancer           Epithelial tumor            38/80                        DGGE              2
  Smith et al. \[[@R34]\]     2001               Caucasians   UK                Renal cell carcinoma      Epithelial tumor            40/65                        DGGE              2
  Jiang et al. \[[@R21]\]     2005               Asians       India             colorectal cancer         Epithelial tumor            301/291                      PCR-RFLP          7
  Jiang et al. \[[@R21]\]     2005               Asians       India             colorectal cancer         Epithelial tumor            301/291                      PCR-RFLP          7
  Siezen et al.\[[@R24]\]     2006               Caucasians   The netherlands   colorectal cancer         Epithelial tumor            204/399                      DNA sequence      8
  Siezen et al. \[[@R24]\]    2006               Caucasians   The netherlands   colorectal cancer         Epithelial tumor            487/750                      DNA sequence      8
  Kuriki et al. \[[@R17]\]    2006               Asians       Japanese          colorectal cancer         Epithelial tumor            128/238                      PCR-TCCP          8
  Kuriki et al. \[[@R17]\]    2006               Asians       Japanese          colorectal cancer         Epithelial tumor            257/771                      PCR-TCCP          7
  Wang et al. \[[@R41]\]      2006               mixed        USA               lymphoma                  Non-epithelial tumor        705/609                      TaqMan            8
  Vogel et al. \[[@R23]\]     2007               Caucasians   Denmark           colorectal cancer         Epithelial tumor            355/753                      Not available     8
  Mossner et al.\[[@R42]\]    2007               Caucasians   German            melanoma                  Non-epithelial tumor        335/355                      PCR-RFLP          7
  Mossner et al. \[[@R42]\]   2007               Caucasians   German            melanoma                  Non-epithelial tumor        497/435                      PCR-RFLP          7
  Chang et al.\[[@R33]\]      2008               Asians       China             ampulla of vater cancer   Epithelial tumor            47/786                       TaqMan            7
  Chang et al. \[[@R33]\]     2008               Asians       China             bile duct cancer          Epithelial tumor            127/786                      TaqMan            7
  Doecke et al.\[[@R38]\]     2008               mixed        Australia         esophageal cancer         Epithelial tumor            260/1352                     sequencing        7
  Doecke et al. \[[@R38]\]    2008               mixed        Australia         esophageal cancer         Epithelial tumor            301/1352                     sequencing        7
  Doecke et al. \[[@R38]\]    2008               mixed        Australia         esophageal cancer         Epithelial tumor            213/1352                     sequencing        7
  Chang et al. \[[@R33]\]     2008               Asians       China             gallbladder cancer        Epithelial tumor            237/786                      TaqMan            7
  Wu et al. \[[@R35]\]        2011               Asians       China             breast cancer             Epithelial tumor            291/589                      RT-PCR            7
  Wei et al. \[[@R37]\]       2013               Asians       China             breast cancer             Epithelial tumor            216/216                      MALDI-TOF MS      3
  Jeon et al. \[[@R39]\]      2013               Asians       China             gastric cancer            Epithelial tumor            196/397                      TaqMan            7
  Park et al. \[[@R36]\]      2014               Asians       Korea             breast cancer             Epithelial tumor            456/461                      MALDI-TOF MS      6
  Our study                   2017               Asians       China             lung cancer               Epithelial tumor            521/1030                     SNPscan           7

DGGE: denaturing gradient gel electrophoresis.

PCR-RFLP: polymerase chain reaction-restriction fragment length polymorphism.

PCR-CTPP: polymerase chain reaction with confronting two-pair primers.

RT-PCR: reverse transcription-polymerase chain reaction.

MALDI-TOF MS: Matrix-Assisted Laser Desorption/Ionization Time of Flight Mass Spectrometry.

###### Distribution of *PPARG* c.1347C\>T polymorphism genotype and allele

  Study                       Publication year   case   control   case     contraol   HWE                                       
  --------------------------- ------------------ ------ --------- -------- ---------- ----- --------- ----- ------ ----- ------ -----
  Zhou et al. \[[@R40]\]      2000               31     21        0        70         10    0         21    83     10    150    Yes
  Zhou et al. \[[@R40]\]      2000               33     10        1        49         11    0         12    76     11    109    Yes
  Smith et al. \[[@R34]\]     2001               27     7         0        18         9     0         7     61     9     45     Yes
  Smith et al. \[[@R34]\]     2001               17     3         0        18         9     0         3     37     9     45     Yes
  Smith et al. \[[@R34]\]     2001               53     12        4        70         10    0         20    118    10    150    Yes
  Smith et al. \[[@R34]\]     2001               27     4         0        52         12    1         4     58     14    116    Yes
  Smith et al. \[[@R34]\]     2001               19     9         0        18         9     0         9     47     9     45     Yes
  Smith et al. \[[@R34]\]     2001               20     6         0        70         10    0         6     46     10    150    Yes
  Smith et al. \[[@R34]\]     2001               30     6         2        70         10    0         10    66     10    150    Yes
  Smith et al. \[[@R34]\]     2001               29     11        0        52         12    1         11    69     14    116    Yes
  Jiang et al. \[[@R21]\]     2005               37     19        3        221        66    4         25    93     74    508    Yes
  Jiang et al. \[[@R21]\]     2005               173    61        8        221        66    4         77    407    74    508    Yes
  Siezen et al. \[[@R24]\]    2006               155    42        4        307        79    4         50    352    87    693    Yes
  Siezen et al. \[[@R24]\]    2006               380    92        7        555        162   9         106   852    180   1272   Yes
  Kuriki et al. .\[[@R17]\]   2006               92               35^\*^   117              61^\*^                              Yes
  Kuriki et al. .\[[@R17]\]   2006               184              73^\*^   543              226^\*^                             Yes
  Wang et al. .\[[@R41]\]     2006               537    150       18       459        137   13        186   1224   163   1055   Yes
  Vogel et al. \[[@R23]\]     2007               255    96        4        557        181   15        104   606    211   1295   Yes
  Mossner et al. \[[@R42]\]   2007               242    73        20       273        73    7         113   557    87    619    Yes
  Mossner et al. \[[@R42]\]   2007               377    113       7        316        111   8         127   867    127   743    Yes
  Chang et al. \[[@R33]\]     2008               27     18        2        457        284   41        22    72     366   1198   Yes
  Chang et al. \[[@R33]\]     2008               74     44        8        457        284   41        60    192    366   1198   Yes
  Doecke et al. \[[@R38]\]    2008               190    65        5        1068       270   14        75    445    298   2406   Yes
  Doecke et al. \[[@R38]\]    2008               223    72        6        1068       270   14        84    518    298   2406   Yes
  Doecke et al. \[[@R38]\]    2008               170    41        2        1068       270   14        45    381    298   2406   Yes
  Chang et al. \[[@R33]\]     2008               127    95        15       457        284   41        125   349    366   1198   Yes
  Wu et al. \[[@R35]\]        2011               162    110       19       328        219   40        148   434    299   875    Yes
  Wei et al. \[[@R37]\]       2013               115    69        15       122        69    9         99    299    87    313    Yes
  Jeon et al. .\[[@R39]\]     2013               104    75        12       220        141   22        99    283    185   581    Yes
  Park et al. \[[@R36]\]      2014               320    126       8        311        117   15        142   766    147   739    Yes
  Our study                   2017               297    198       26       631        355   43        250   792    441   1617   Yes

^\*^Indicates TT+CT

HWE: Hardy--Weinberg equilibrium.

Overall, we found a significant association between *PPARG* c.1347C\>T polymorphism and the increased risk of cancer (T vs. C: OR, 1.13; 95% CI, 1.03--1.23; *P* = 0.006; TT vs. CC: OR, 1.29; 95% CI, 1.07--1.56; *P* = 0.008, CT/TT vs. CC: OR, 1.11; 95% CI, 1.02--1.21; *P* = 0.014 and TT vs. CT/CC: OR, 1.26; 95% CI, 1.04--1.52; *P* = 0.016; Table [6](#T6){ref-type="table"} and Figure [2](#F2){ref-type="fig"}).

![Meta-analysis of the association between *PPARG* c.1347C\>T polymorphism and cancer risk (TT/CT vs. CC\
random--effects model).](oncotarget-08-102277-g002){#F2}

###### Results of the meta-analysis from different comparative genetic models

                              No. of studies   T vs. C               TT vs. CC   TT+CT vs. CC   TT vs. CT+CC                                                                                                                                                 
  --------------------------- ---------------- --------------------- ----------- -------------- -------------- --------------------- ----------- ------- ------- --------------------- ----------- ------- ------- --------------------- ----------- ------- -------
  Total                       31               **1.13(1.03-1.23)**   **0.006**   39.5%          0.016          **1.29(1.07-1.56)**   **0.008**   6.6%    0.370   **1.11(1.02-1.21)**   **0.014**   26.9%   0.086   **1.26(1.04-1.52)**   **0.016**   1.9%    0.436
  Ethnicity                                                                                                                                                                                                                                                  
  Asians                      15               **1.10(1.01-1.20)**   **0.033**   0.1%           0.444          1.19(0.94-1.51)       0.149       6.4%    0.382   1.10(1.00-1.21)       0.058       0.0%    0.704   1.15(0.91-1.45)       0.248       0.0%    0.447
  Caucasians                  9                1.14(0.91-1.43)       0.246       61.1%          0.008          1.33(0.87-2.03)       0.192       19.5%   0.275   1.14(0.89-1.45)       0.290       59.8%   0.011   1.32(0.87-2.02)       0.196       17.4%   0.293
  Mixed                       7                **1.26(1.02-1.55)**   **0.034**   50.5%          0.059          **1.70(1.08-2.68)**   **0.022**   1.7%    0.405   **1.17(1.01-1.35)**   **0.032**   34.3    0.166   **1.67(1.06-2.63)**   **0.027**   0.0%    0.462
  Cancer type                                                                                                                                                                                                                                                
  Biliary tract cancer        3                1.10(0.92-1.31)       0.288       0.0%           0.729          1.21(0.76-1.93)       0.416       0.0%    0.848   1.12(0.90-1.38)       0.322       0.0%    0.675   1.17(0.74-1.84)       0.508       0.0%    0.865
  Breast cancer               3                1.01(0.87-1.17)       0.890       0.0%           0.504          0.96(0.63-1.45)       0.843       47.8%   0.147   1.03(0.86-1.23)       0.785       0.0%    0.834   0.95(0.63-1.43)       0.810       48.1%   0.145
  Colorectal cancer           7                1.10(0.97-1.25)       0.148       50.1%          0.143          1.48(0.95-2.30)       0.084       32.8%   0.299   1.06(0.94-1.21)       0.353       19.6%   0.370   1.45(0.93-2.25)       0.099       27.2%   0.345
  Esophageal cancer           3                **1.22(1.04-1.44)**   **0.016**   33.7%          0.221          1.69(0.90-3.18)       0.102       0.0%    0.621   **1.23(1.03-1.47)**   **0.025**   27.7%   0.251   1.62(0.86-3.05)       0.131       0.0%    0.671
  Glioblastoma                2                **2.54(1.43-4.54)**   **0.002**   53.8%          0.141          \-                    \-          \-      \-      2.70(0.86-8.41)       0.087       68.4%   0.075   \-                    \-          \-      \-
  Melanoma                    2                1.11(0.66-1.84)       0.698       84.5%          0.011          1.58(0.37-6.73)       0.539       78.4%   0.031   1.04(0.68-1.60)       0.849       72.2%   0.058   1.59(0.40-6.36)       0.514       76.5%   0.039
  Ovarian cancer              3                1.01(0.55-1.86)       0.975       17.6%          0.297          \-                    \-          \-      \-      1.05(0.54-2.02)       0.887       14.5%   0.311   \-                    \-          \-      \-
  Other cancers               8                1.11(0.99-1.25)       0.085       39.1%          0.118          1.35(0.96-1.91)       0.088       0.0%    0.471   1.11(0.96-1.28)       0.148       25.2%   0.228   1.29(0.92-1.82)       0.141       0.0%    0.476
  The origin of cancer cell                                                                                                                                                                                                                                  
  Epithelial tumor            26               **1.11(1.04-1.19)**   **0.003**   20.5%          0.183          **1.25(1.01-1.54)**   **0.036**   0.0%    0.483   **1.11(1.03-1.20)**   **0.007**   0.0%    0.500   1.21(0.98-1.48)       0.074       0.0%    0.547
  Non-epithelial tumor        5                1.29(0.91-1.83)       0.161       76.9%          0.002          1.54(0.96-2.46)       0.073       46.9%   0.130   1.27(0.87-1.86)       0.220       75.6%   0.003   1.55(0.97-2.47)       0.069       42.2%   0.158
  Quality scores                                                                                                                                                                                                                                             
  ≥7.0                        19               **1.01(1.03-1.18)**   **0.005**   27.0%          0.146          **1.30(1.06-1.59)**   **0.012**   0.0%    0.540   **1.09(1.01-1.17)**   **0.021**   5.7%    0.386   **1.26(1.03-1.54)**   **0.025**   0.0%    0.614
  \<7.0                       12               1.30(0.95-1.77)       0.099       54.4%          0.012          1.28(0.77-2.14)       0.348       38.8%   0.133   1.29(0.93-1.78)       0.129       48.7%   0.029   1.25(0.75-2.08)       0.388       37.7%   0.141

In a subgroup analysis by the ethnicity, evidence of significant association between *PPARG* c.1347C\>T polymorphism and increased risk of cancer were also found among Asians, and mixed populations, but not Caucasians (Table [6](#T6){ref-type="table"}). In a subgroup analysis by cancer type, c.1347C\>T polymorphism was associated with the risk of esophageal cancer, and glioblastoma, but not biliary tract, breast, colorectal, melanoma, ovarian and other cancers (Table [6](#T6){ref-type="table"}). In addition, in a subgroup analysis by the origin of cancer cell, evidence of significant association between *PPARG* c.1347C\>T polymorphism and an increased risk of cancer were also found among epithelial tumor (Table [6](#T6){ref-type="table"}).

The quality score of the enrolled studies was determined by using Newcastle-Ottawa Quality Assessment Scale \[[@R43]\].The results indicated that nineteen were high-quality and twelve were low-quality (Table [7](#T7){ref-type="table"}). When we excluded the low-quality studies, the results were not substantially altered suggesting the reliability of our findings (Table [6](#T6){ref-type="table"}).

###### Quality assessment of the included studies in meta-analysis

  Study                       Year   Selection   Comparability of the cases and controls   Exposure   Total Stars                       
  --------------------------- ------ ----------- ----------------------------------------- ---------- ------------- ---- ---- ---- ---- ---
  Zhou et al. \[[@R40]\]      2000   ↔           ↔                                         \-         ↔             \-   ↔    \-   \-   4
  Zhou et al. \[[@R40]\]      2001   ↔           ↔                                         \-         ↔             \-   ↔    \-   \-   4
  Smith et al. \[[@R34]\]     2001   \-          \-                                        \-         ↔             ↔    \-   \-   \-   2
  Smith et al. \[[@R34]\]     2001   \-          \-                                        \-         ↔             ↔    \-   \-   \-   2
  Smith et al. \[[@R34]\]     2001   \-          \-                                        \-         ↔             ↔    \-   \-   \-   2
  Smith et al. \[[@R34]\]     2001   \-          \-                                        \-         ↔             ↔    \-   \-   \-   2
  Smith et al. \[[@R34]\]     2001   \-          \-                                        \-         ↔             ↔    \-   \-   \-   2
  Smith et al. \[[@R34]\]     2001   \-          \-                                        \-         ↔             ↔    \-   \-   \-   2
  Smith et al. \[[@R34]\]     2001   \-          \-                                        \-         ↔             ↔    \-   \-   \-   2
  Smith et al. \[[@R34]\]     2001   \-          \-                                        \-         ↔             ↔    \-   \-   \-   2
  Jiang et al. \[[@R21]\]     2005   ↔           ↔                                         \-         ↔             ↔↔   ↔    ↔    \-   7
  Jiang et al. \[[@R21]\]     2005   ↔           ↔                                         \-         ↔             ↔↔   ↔    ↔    \-   7
  Siezen et al. \[[@R24]\]    2006   ↔           ↔                                         ↔          ↔             ↔↔   ↔    ↔    \-   8
  Siezen et al. \[[@R24]\]    2006   ↔           ↔                                         ↔          ↔             ↔↔   ↔    ↔    \-   8
  Kurikin et al. \[[@R17]\]   2006   ↔           ↔                                         \-         ↔             ↔↔   ↔    ↔    ↔    8
  Kurikin et al. \[[@R17]\]   2006   ↔           ↔                                         \-         ↔             ↔↔   ↔    ↔    \-   7
  Wang et al. \[[@R41]\]      2006   ↔           ↔                                         ↔          ↔             ↔↔   ↔    \-   ↔    8
  Vogel et al. \[[@R23]\]     2007   ↔           ↔                                         ↔          ↔             ↔↔   ↔    ↔    \-   8
  Mossner et al. \[[@R42]\]   2007   ↔           ↔                                         \-         ↔             ↔↔   ↔    ↔    \-   7
  Mossner et al. \[[@R42]\]   2007   ↔           ↔                                         \-         ↔             ↔↔   ↔    ↔    \-   7
  Chang et al. \[[@R39]       2008   ↔           ↔                                         \-         ↔             ↔↔   ↔    ↔    \-   7
  Chang et al. \[[@R39]       2008   ↔           ↔                                         \-         ↔             ↔↔   ↔    ↔    \-   7
  Chang et al. \[[@R39]       2008   ↔           ↔                                         \-         ↔             ↔↔   ↔    ↔    \-   7
  Doecke et al. \[[@R38]\]    2008   ↔           ↔                                         ↔          ↔             ↔↔   ↔    \-   \-   7
  Doecke et al. \[[@R38]\]    2008   ↔           ↔                                         ↔          ↔             ↔↔   ↔    \-   \-   7
  Doecke et al. \[[@R38]\]    2008   ↔           ↔                                         ↔          ↔             ↔↔   ↔    \-   \-   7
  Wu et al. \[[@R35]\]        2011   ↔           ↔                                         \-         ↔             ↔↔   ↔    ↔    \-   7
  Wei et al. \[[@R37]\]       2013   ↔           \-                                        \-         ↔             \-   ↔    \-   \-   3
  Jeon et al. \[[@R39]\]      2013   \-          ↔                                         ↔          ↔             ↔↔   ↔    ↔    \-   7
  Park et al. \[[@R36]\]      2014   ↔           ↔                                         \-         \-            ↔↔   ↔    ↔    \-   6
  Our study                   2017   ↔           ↔                                         \-         ↔             ↔↔   ↔    ↔    \-   7

In this meta-anlysis, we used Begg\'s test and Egger\'s test to measure the publication bias. The results demonstrated that there was no significant bias in any genetic model (T vs. C: Begg\'s test *P* = 0.442, Egger\'s test *P* = 0.196; TT vs. CC: Begg\'s test *P* = 0.442, Egger\'s test *P* = 0.167; CT/TT vs. CC: Begg\'s test *P* = 0.634, Egger\'s test *P* = 0.244; TT vs. CT/CC: Begg\'s test *P* = 0.333, Egger\'s test *P* = 0.149; Figure [3](#F3){ref-type="fig"}). Using the one-way method (excluding an individual study in turn), sensitivity analysis was carried out to determine stability of our findings (Figure [4](#F4){ref-type="fig"}). The results indicated that our findings were stable and reliable.

![Begg\'s funnel plot of meta--analysis of the association between *PPARG* c.1347C\>T polymorphism and cancer risk (TT/CT vs. CC compare genetic model, random--effects model)](oncotarget-08-102277-g003){#F3}

![Sensitivity analysis of the influence of TT/CT vs. CC comparison (random--effects estimates for *PPARG* c.1347C \> T polymorphism)](oncotarget-08-102277-g004){#F4}

Significant heterogeneities were found in this meta-analysis. Since the origin of cancer cell, quality score, ethnicity and cancer type could affect the results of meta--analysis, we carried out subgroup analyses by these factors and the findings were presented in Table [6](#T6){ref-type="table"}. The results indicated that melanoma, non-epithelial tumor, Caucasians and quality score \< 7.0 subgroups may contribute to the major heterogeneity. As shown in Table [6](#T6){ref-type="table"}, significant heterogeneity was found in allele comparison, thus meta-regression was also performed to explore the source of heterogeneity. We found that quality score might contributed to major heterogeneity, which can explain 64.27% heterogeneity (Tau1 = 0.019100,Tau2 = 0.006824, respectively).

DISCUSSION {#s3}
==========

The etiology of cancer was very complex. It is thought that many environmental and genetic factors may play important roles in the development of cancer. Multiple lines of evidence indicate a vital role for genetics in determining risk for cancer. PPARG is a member of the peroxisome proliferator-activated receptors (PPARs). PPARs interact with retinoid X receptors and then regulate the transcription process of many genes. PPARG has been implicated in the development of various diseases involving obesity, diabetes, inflammation, atherosclerosis and cancer \[[@R44]--[@R47]\]. PPARG is expressed in various cancer cells. There are accumulating evidences that obesity/overweight, type 2 diabetes, inflammation, and malignancy are etiologically related \[[@R48], [@R49]\]. Being at the crossroads of multiple diseases, PPARG may be a key component for understanding the pathophysiology of cancer. In this study, we explored the relationship of *PPARG* c.1347C\>T polymorphism with NSCLC risk. Then, we conducted a comprehensive meta-analysis to further understand the potential role of this SNP for the susceptibility to overall cancer. In the case-control study, we found an association between *PPARG* c.1347C\>T polymorphism and a tendency to increased risk of NSCLC. Along with a meta-analysis, we found that *PPARG* c.1347C\>T polymorphism was associated with the increased risk of overall cancer. To the best of our knowledge, this study is the first case-control study focusing on the association between *PPARG* c.1347C\>T polymorphism and NSCLC risk in Asians. And we first confirmed the relationship between this SNP and overall cancer risk.

With the increasing studies on genetic association, it is necessary to analyze the available data to obtain robust, replicable results. Considering the fact that a common SNP may make a small-to-moderate contribution to the risk of cancer, this pooled-analysis urges the necessity of adequate sample sizes to get a precise measurement between *PPARG* c.1347C\>T polymorphism and the development of cancer. Several individual studies have reported positive signals of *PPARG* c.1347C\>T polymorphism with cancer risk \[[@R21], [@R38], [@R40]\]; however, others observed null association. Recently, a meta-analysis reported that this polymorphism was not associated with cancer risk \[[@R31]\]; however, this pooled-analysis only included four case-control studies. In this updated meta-analysis, overall findings among 21,404 subjects, evidence of significant association between this polymorphism and cancer risk were found, even in Asians, mixed populations, esophageal cancer, glioblastoma and epithelial tumor subgroups. In *PPARG* exon 6, a C to T substitution is a synonymous polymorphism which encodes histidine either with *PPARG* c.1347 C or T allele. The findings of previous epidemiological studies showed a relationship of this polymorphism with metabolic diseases such as type 2 diabetes and atherosclerosis \[[@R50]--[@R53]\]. It is proposed that the C to T substitution may modulate the expression of PPARG by altering mRNA processing or translation. A tendency of increased risk was observed for *PPARG* c.1347C\>T polymorphism with NSCLC risk, and an increased risk was also found in the subsequent meta-analysis. These consistent findings demonstrated that *PPARG* c.1347C\>TC\>T polymorphism might influence the development of cancer. In the future, further evaluations with detailed environmental factors are warranted to confirm these results.

Additionally, some potential limitations should be further addressed when interpreting our findings. First, the design of our case-control study was hospital-based, and the selecting bias might have occurred. Second, in this meta-analysis, the included studies based on the published studies, unpublished articles might fail to be retrieved. Third, since the significant heterogeneities were found in this meta-analysis, our findings should be interpreted with cautions. Fourth, lack of the data on environmental factors (e.g. lifestyle, fasting plasma glucose, total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, serum triglycerides etc.), the corresponding subgroup analyses were not conducted. Finally, we only focused on c.1347C\>T polymorphism in *PPARG* gene, and did not consider other susceptibility genes or polymorphisms.

In conclusion, this case-control study in Eastern Chinese Han populations, along with a comprehensive meta-analysis, identify the association of *PPARG* c.1347C\>T polymorphism with an increased risk of cancer, even in Asians, esophageal cancer, glioblastoma and epithelial tumor subgroups. Nevertheless, for some practical reasons, we hope that more case-control studies with the detailed environmental data to further explore the molecular mechanism of *PPARG* c.1347C\>T polymorphism with development of cancer.

MATERIALS AND METHODS {#s4}
=====================

Subjects {#s4_1}
--------

Genotyping analyses were carried out on genomic DNA of 521 NSCLC patients and 1,030 unrelated controls. All participants were come from Eastern Chinese Han population. The major included criterion of NSCLC patients were: (A) living in Eastern China area; (B) NSCLC was confirmed by pathological examination; (C) without autoimmune disease. The NSCLC patients comprised unrelated subjects who had been treated in Affiliated People\'s Hospital of Jiangsu University and Fujian Medical University Union Hospital. The blood samples were collected from January 2014 to December 2016. Index cases were first diagnosed with NSCLC. All patients gave a written informed consent.

The controls included healthy blood donors collected in the same hospitals, having the same ethnic background and similar lifestyle as the NSCLC patients. The controls were biologically unrelated to the NSCLC cases and were cancer-free. The age distribution of NSCLC cases and non-cancer controls was nearly identical (controls: 60.34 ± 9.11 years; cases: 59.76 ± 10.71years; *P* = 0.268). The sex distribution of NSCLC cases and controls was well-matched (*P* = 0.453). According to the guidelines of Chinese blood donation, each participant was examined by a questionnaire and wrote his/her informed consent. The controls were randomly collected during the years 2014--2016. The study was approved by the Ethics Committee of Jiangsu University (Zhenjiang, China) and Fujian Medical University (Fuzhou, China).

DNA extraction and genotyping {#s4_2}
-----------------------------

EDTA anticoagulant vacutainer tube was used to collect blood sample. We used DNA Kit (Promega, Madison, USA) to extract the genomic DNA from the whole blood.

*PPARG* c.1347C\>T polymorphism (NP_005028.4: p.His449His) was analyzed using SNPscan^TM^ genotyping assay (Genesky Biotechologies Inc., Shanghai, China). The SNP assays were confirmed by re-genotyping sixty-two (4%) randomly selected samples.

Statistical analysis {#s4_3}
--------------------

The continuous variables (e.g. age, and BMI) are presented as the mean ± SD. We used Student\'s *t*-test to examine the difference of continuous variables between NSCLC patients and non-cancer controls. In addition, we used *χ*^2^ test to determine the difference of categorical variables (e.g. genotypes, smoking status, alcohol consumption, sex, age and BMI). HWE test in controls was undertaken using an internet-based *χ*^2^ goodness-of-fit test (<http://ihg.gsf.de/cgi-bin/hw/hwa1.pl>). Genotype-specific ORs with their corresponding 95%CIs and *P*-values were calculated by SAS 9.4 software for windows (SAS Institute, Cary, NC). *P*-values were presented using two-sided *χ*^2^-test.

Meta-analysis {#s4_4}
-------------

To further determine the relationship between *PPARG* c.1347C\>T variants and cancer susceptibility, we carried out a meta-analysis. All studies focusing on the association between this polymorphism and cancer risk were collected by searching of PubMed and Embase databases (the last search update on June 12, 2017). The search was performed with the terms of (Peroxisome proliferator activated receptor gamma or PPARG) and (NP_005028.4: p.His449His or His449His or H449H or C161T or C1431T or rs3856806 or c.1347C\>T) and (polymorphism or variant) and (cancer or carcinoma). Additional studies were also supplemented by a hand search of the corresponding references in retrieved articles. In this study, the language of publication was restricted to English. In our analysis, eligible studies had to meet the inclusion criteria: (1) focusing on the association between *PPARG* c.1347C\>T polymorphism and cancer risk; (2) designed as a case-control or cohort study; (3) data could be extracted from the publications (genotypes of cases and controls); (4) published in English language; (5) genotype distribution was consistent with HWE in controls. Two authors (H. Ding and H. Qiu) extracted the detailed information from the eligible publications independently. When they met the disagreement, the third reviewer (Y. Chen) was invited to discuss every item. Finally, a consensus was reached. The following characteristics were selected and collected: the first author, year, country, ethnicity, genotyping method, cancer type, sample size, the origin of cancer cell and genotype frequencies.

For each included study, we analyzed HWE in controls using goodness-of-fit test mentioned above and *P* \< 0.05 was defined as violation of HWE. Crude ORs with their 95% CIs were used to examine the strength of relationship between *PPARG* c.1347C\>T polymorphism and cancer susceptibility. The pooled ORs for this polymorphism were performed under four genetic models (e.g. TT+CT vs. CC, TT vs. CC+CT, TT vs. CC and T vs. C). Stratified analyses were extensively performed with respect to origin of cancer cell, ethnicity, cancer type and quality scores. The heterogeneity across the eligible studies was tested by using a χ^2^-based Q-test and *I^2^* test \[[@R54]\]. The pooled OR was calculated by a random-effects model (the Der-Simonian and Laird method) if *I^2^* \> 50% or *P* \< 0.1, which indicated that heterogeneity was significant \[[@R55], [@R56]\]. Otherwise, the pooled OR was assessed by a fixed-effects model (the Mantel-Haenszel method) \[[@R57]\]. Removing each study in turn, sensitivity analysis was carried out by one-way method to determine the stability of the results. Additionally, Begg\'s test and Egger\'s linear regression test were conducted to assess the potential publication bias \[[@R58]\] and *P* \< 0.1 was regarded as a bias. Meta-regression was conducted to analyze the source of heterogeneity \[[@R59]\]. In the present meta-analysis, all statistical analyses were performed by using the STATA 12.0 software for windows (Stata Corporation, College Station, Texas). A *P* value (two-sided) less than 0.05 were considered significant. Newcastle-Ottawa Quality Assessment Scale was harnessed to determine the quality score of the enrolled studies. If scores ≥ 7 stars, the study was defined as high-quality \[[@R43], [@R60]\].
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